www.tajpharma.com

Lypsyiam® Perampanel is used alongside other medicines in the treatment of partial seizures, which is a type of epilepsy . Lypsyiam® Perampanel is a first-in-class selective, non-competitive antagonist of the AMPA glutamate receptor.





Lypsyiam® (perampanel) Tablets is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older."

Lypsyiam® (perampanel) is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in patients with epilepsy aged 12 years and older.

About Lypsyiam®

Lypsyiam® (perampanel) is a selective, non-competitive AMPA receptor antagonist discovered by the research teams at Taj laboratories. The development of an AMPA antagonist compound with a favourable pharmacokinetic and safety profile arose after the AMPA receptor was identified as a promising target for drug development. The AMPA receptor is widely present in almost all excitatory neurons. It is believed to play a role in a large number of central nervous system diseases with similar neuropathology.

Lypsyiam® — THE FIRST AND ONLY LICENSED AMPA RECEPTOR ANTAGONIST Reduce postsynaptic hyperexcitation

- Lypsyiam® is a highly selective, noncompetitive, AMPA receptor antagonist 1,2
- Fycompa reduces neuronal hyperexcitation associated with seizures by targeting glutamate activity at postsynaptic AMPA receptors 1,2,4.

Lypsylam® must be titrated, according to individual patient response, in order to optimise the balance between efficacy and tolerability.

Lypsyiam® Perampanel should be taken orally once daily before bedtime.

Lypsyiam® Perampanel at doses of 4 mg/day to 12 mg/day has been shown to be effective therapy in partial-onset seizures.

ONE TABLET / ONCE DAILY

NEW LYPSIAM

(perampanel) Tablets (iii 2/4/6/8/10 & 12 mg

Food and Drug Administration (FDA) approved .Prescription Only (POM)

A Taj Pharma"India Product